The Protease Inhibitor Lopinavir, Boosted with Ritonavir, as Treatment for COVID-19: A Rapid Review | Zendy

Jienchi Dorward | Zendy; Oghenekome Gbinigie | Zendy; Ting Cai | Zendy; Nia Roberts | Zendy; Nigel Garrett | Zendy; Gail Hayward | Zendy; Christopher Butler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Protease Inhibitor Lopinavir, Boosted with Ritonavir, as Treatment for COVID-19: A Rapid Review

Author(s) -

Jienchi Dorward,

Oghenekome Gbinigie,

Ting Cai,

Nia Roberts,

Nigel Garrett,

Gail Hayward,

Christopher Butler

Publication year - 2019

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp3385

Subject(s) - lopinavir , ritonavir , medicine , lopinavir/ritonavir , randomized controlled trial , retrospective cohort study , confounding , covid-19 , viral load , virology , human immunodeficiency virus (hiv) , disease , antiretroviral therapy , infectious disease (medical specialty)

The HIV protease inhibitor lopinavir, boosted with ritonavir, has been used off-label to treat COVID-19. We aimed to synthesize the clinical evidence for lopinavir/ritonavir as a treatment for COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research